Mike Loftus Newly Appointed Clinical Trials Committee Board Member of BioNJ
Media inquiries about Integrium Clinical Research or its services should be directed to:
Tel (657) 900-5232
Tustin, Calif. - December 2, 2014
Integrium Executive Director of Business Development, Mike Loftus, has been selected to represent BioNJ leadership on the Clinical Trials Committee Board. Mike has brought visibility and a depth of new opportunity while enhancing the climate of biotechnology in the state of New Jersey. His networking sphere encompasses: Venture Capital, Private Equity, Pharmaceutical, Biotechnology, Medical Device, Life Sciences Law, Audit and Public Policy firms that are part of or interested in Capital Markets and the Research and Development process.
As a long standing member of BioNJ, Integrium remains an active participant, bringing forward prospective Biotechnology, Pharmaceutical and Medical Device Organizations to the Biotech Ecosystem of New Jersey and beyond. The BioNJ Breakfast Briefing, previously sponsored by Integrium, allows members and contributors of life sciences companies the ability to network and educate. Whilst manufacturing innovation and attracting drug discovery through such events, www.integrium.com continues to attend BioNJ gatherings including the first and second Annual BioNJ CEO Summit, The Gateway Gala Annual Dinner meeting, and the International BioPartnering Conference.
BioNJ represents and brings together the biotechnology ecosystem within the state of New Jersey. Committed to developments contributing to the industry's growth and prosperity since 1994, BioNJ has built a profound network of 400 member companies representing research-based life sciences companies and stakeholders. Dedicated members and BioNJ leadership collaborate to further engage in opportunities ensuring science is supported, companies are created, drugs are developed, and patients are paramount. BioNJ voices their mission as the Gateway to Health.
For more information, please contact Mike Loftus
About Integrium, LLC
Integrium Clinical Research specializes in the strategy, study design, and execution of Phase I-IV clinical trials, with an expertise in Proof of Concept trials. The firm has strong clinical trial experience in a range of therapeutic indications including cardiovascular, metabolic, renal, inflammatory, dermatology, regenerative, orphan, and wound healing drug development. It has a strong reputation for delivering high-quality management of global clinical development programs and service to its clients. Combining the Integrium Clinical Excellence (ICE) study start-up and management methodology, and therapeutic expertise leads sponsors to more confident, better-informed drug and device development decisions. For more information please visit www.integrium.com.